Piramal Enterprises
Piramal Enterprises
Shareholder Return: 3-year, Sales Growth: 3-year CAGR, Return On Equity: 3-year average
At a Glance
-
Shareholder Return296%
-
Sales Growth24%
-
Return on Equity14 %
Why Super 50
Under the group leadership of Ajay Piramal, the strategy and positioning of the flagship listed firm has been transformed from a pharmaceutical-led to a diversified conglomerate. Growth is being driven by the financial services businesses, which include wholesale and real estate development financing, and retail exposure through the acquisition of stakes in Shriram Group companies. Fresh growth will be built on the platforms of a housing finance business. Investors have seen a 28 percent annualised return over the past 20 years.
